First-line triplet therapy may expand clinical benefit for advanced clear cell renal cell carcinoma (ccRCC). The phase Ib/II KEYMAKER-U03 Substudy 03A (NCT04626479) investigated novel pembrolizumab (pembro)-based regimens in this setting.
Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
Annals of Oncology | | C. Suarez, C. Rojas, S.J. Shin, P.Yanez Weber, L. Albiges, R. Motzer, H. Hammers, A. Peer, J-L. Lee, W.H. Miller, T. Waddell, V. Neiman, D. Keizman, A.Zwenger Kloster, A. Weickhardt, R. Dziadziuszko, L. Suttner, M. Sharma, J.E. Burgents, T. Powles
Topics: colorectal-cancer, kidney-cancer, cervical-cancer, immunotherapy, clinical-trials, research